실시간
Endpoints NewsRegeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3Lonza NewsBristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement - CHEManagerEndpoints NewsFDA approves AstraZeneca’s baxdrostat for certain patients with hypertensionFierceBiotechIpsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3Ningbo HEALTH Gene Technologies Co., Ltd.$1 Billion Human Identification Market Analysis by Product, Technology, Application, End User and Region - Forecast to 2031 - Yahoo! Finance CanadaFierceBiotechAnalysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trialBioPharma DiveUnlocking more value from mature drug products through strategic outsourcingGCCGCC Hydroxypropyl Methylcellulose Market Report 2026–2034 | Construction and Pharma Trends - vocal.mediaFierceBiotechArdent Health taps Fujifilm’s AI-enabled patient imaging platformFierceBiotechExecuting biomarker-driven oncology trials10x Genomics NewsAssessing 10x Genomics (TXG) Valuation After Q1 2026 Results And Rising AI Trading Interest - simplywall.stLonza NewsLonza Group AG stock (CH0013841017): focus shifts to growth after strategic review and margin reset - AD HOC NEWS
이 기사는 아카이브에서 찾을 수 없습니다.